ReShape Lifesciences™ is the weight loss company that offers products and solutions to help people with obesity throughout the treatment continuum. Our current portfolio includes surgical & non-surgical weight loss treatments, such as the Lap-Band® Program, the ReShape Vest™ & the ReShapeCare™ Program. The company is rapidly advancing its innovative technologies to broadly benefit patients, healthcare providers & stakeholders worldwide. The Lap-Band helps patients take control over their weight, because only the Lap-Band can be tightened or loosened as their body or physical needs change, helping provide sustainable weight loss over the long term. The Lap-Band is the only FDA approved laparoscopic weight loss procedure commercially available in the U.S. & covered by most insurance companies. It gives patients control over their body too, because it’s the safest weight loss surgery available, with the lowest complication & mortality rate, because it does not cut out the majority of the stomach or reroute intestines. ReShape Lifesciences is committed to advancing the future of weight loss procedures as evidenced by the ReShape Vest. An investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery & is intended to enable rapid weight loss in obese & morbidly obese patients without permanently changing patient anatomy. Currently, the ReShape Vest is in European clinical trials & not commercially available for sale. ReShapeCare™ is a reimbursable, customizable, virtual weight management program that focuses on helping surgical & non-surgical patients treat, manage, & improve the chronic, metabolic disease of obesity, directed by their physician. This evidence-based program increases access to & coordination of care from certified health coaches. Patients can conveniently get the personalized help they need.
Location: United States, California, San Clemente
Employees: 11-50
Total raised: $107M
Founded date: 2002
Investors 2
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | US Venture... | usvp.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.06.2021 | - | $46M | - |
| 17.10.2017 | - | $61M | - |
Mentions in press and media 14
| Date | Title | Description |
| 05.09.2025 | Biorad Medisys Announces Its Entry into the US Market with the Launch of its New Subsidiary Medtimo Inc. | Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidiary Medtimo Inc. The move comes post Biorad Medisys’ completion of acquisition of busine... |
| 23.06.2023 | Life Science Investor Forum: Presentations Now Available for Online Viewing | Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com /EIN News/ -- NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announc... |
| 08.02.2023 | ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering | - |
| 08.02.2023 | ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering | /EIN News/ -- SAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwr... |
| 06.02.2023 | ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering | /EIN News/ -- SAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwr... |
| 06.02.2023 | ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering | - |
| 12.11.2021 | ReShape Lifesciences : Reports Third Quarter and Nine Month 2021 Financial and Operational Results - Form 8-K | ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results Webinar to follow at 8:45 a.m. ET today San Clemente, CA November 11, 2021 - ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-le... |
| 11.11.2021 | ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results | SAN CLEMENTE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported its financial and operational results for the thr... |
| 08.11.2021 | ReShape Lifesciences to Report Third Quarter 2021 Financial and Operational Results on Thursday, November 11, 2021 | SAN CLEMENTE, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced today that it will report its third quarter 2021 financ... |
| 16.08.2021 | ReShape Lifesciences : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K) | ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update Webinar to follow at 8:30 a.m. today San Clemente, CA August 16, 2021 - ReShape Lifesciences Inc. (NASDAQ: RSLS), a leading developer and distributor of mini... |
Show more